Welcome to our dedicated page for BRK SEC filings (Ticker: BRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding Warren Buffett’s latest thoughts or BNSF freight numbers inside Berkshire Hathaway’s 300-plus page filings can feel overwhelming. Each quarter the conglomerate folds insurance float calculations, railroad carload data, and dozens of subsidiary footnotes into one dense report. If you have ever asked “How do I read the Berkshire Hathaway quarterly earnings report 10-Q filing?” this page is built for you.
Stock Titan delivers AI-powered summaries that translate complex accounting into plain English. The platform flags every Berkshire Hathaway insider trading Form 4 transaction, captures material 8-K events, and explains how they might affect cash flow. Real-time alerts ensure you never miss a Berkshire Hathaway Form 4 insider transactions real-time update or a fresh 10-K. Want quick context on deferred tax liabilities? Our engine answers “understanding Berkshire Hathaway SEC documents with AI” in seconds and links you straight to the page that matters.
All filing types are one click away:
- Berkshire Hathaway annual report 10-K simplified—see segment revenue, insurance float, and equity portfolio swings.
- Berkshire Hathaway quarterly earnings report 10-Q filing—track GEICO loss ratios and Precision Castparts margins.
- Berkshire Hathaway proxy statement executive compensation—review director fees and succession planning details.
- Berkshire Hathaway 8-K material events explained—follow acquisitions or stock buyback updates.
- Berkshire Hathaway earnings report filing analysis with AI commentary.
- Berkshire Hathaway executive stock transactions Form 4 with sortable tables.
Whether you monitor dividend capacity, compare year-over-year underwriting profit, or study Berkshire Hathaway SEC filings explained simply for academic research, Stock Titan saves hours and surfaces the insights that drive informed decisions.
RH (NYSE: RH) Form 4 filing dated 06/30/2025 discloses that independent director Mark S. Demilio received an equity grant of 670 restricted shares on 06/26/2025. The award vests in full one year from the grant date and was recorded at a $0 acquisition price, reflecting standard director compensation rather than an open-market purchase. Following the grant, Mr. Demilio’s total beneficial ownership rises to 42,056 RH common shares, comprising 12,717 shares held directly and 29,339 shares held indirectly through two family trusts. No derivative securities were reported. The filing indicates continued alignment between the director’s personal stake and shareholder interests, but it does not involve cash outlay or signal a market-driven buying decision.
On 06/30/2025, Relmada Therapeutics, Inc. (RLMD) filed a Form 4 reporting that officer Chuck Ence received an incentive stock option grant. The award, dated 06/26/2025, covers 400,000 shares of common stock at an exercise price of $0.67 per share. Vesting occurs in 16 equal quarterly installments starting 09/26/2025, with expiration on 06/26/2035. No common shares were purchased or sold; the transaction code was “A” (acquisition from the issuer) and the securities are held directly. After the grant, Ence beneficially owns 400,000 derivative securities. The filing signals continued executive retention efforts and creates potential dilution of up to 400,000 shares if the options are eventually exercised.
FAQ
What is BRK's core business?
How does BRK generate its revenue?
How is BRK structured in terms of business segments?
What differentiates BRK from other conglomerates?
How are Duracell and Johns Manville connected to BRK?
What role does diversification play in BRK's strategy?
How does BRK approach potential acquisitions?
What are some of the key competitive advantages of BRK?
